MediWound Ltd.MDWD
Price (close)
$13.83
Market cap
$177.5M
P/E
—
Revenue (FY)
$17.0M
Net income
-$23.9M
Dividend yield
—
1-year total return
-21.9%
Net margin
-140.8%
Revenue growth
-16.1%
Debt / equity
—
What MediWound Ltd. does.
focused on non-surgical tissue repair. Our solutions selectively remove non-viable hazardous tissue while preserving healthy tissue, offering
a safer and more effective alternative to traditional methods. With robust in-house research, development, and manufacturing capabilities,
the company produces and commercializes cutting-edge biologics for wound and burn care that exceed existing standards of care, improve
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $21.8M | $23.8M | $26.5M | $18.7M | $20.2M | $17.0M |
| Net income | -$9.2M | -$13.6M | -$19.6M | -$6.7M | -$30.2M | -$23.9M |
| Free cash flow | -$7.8M | -$9.4M | -$12.4M | -$16.9M | -$19.9M | -$21.6M |
More on MDWD.
- MediWound Ltd. summary
- MediWound Ltd. financial statements
- MediWound Ltd. key metrics
- MediWound Ltd. health scores and style box
- MediWound Ltd. earnings
- MediWound Ltd. dividends
- MediWound Ltd. valuation
- MediWound Ltd. ownership and insiders
- MediWound Ltd. peers
Figures from MediWound Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.